Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
Elsallab et. al, Cancer Gene Therapy, 2023

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Flugel et al, Nature Review Clinical Oncology, 2023

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Choe e al, JAMA Network Open, 2022

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Amini et al, Nature Review Clinical Oncology, 2022

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein et al, Blood Cancer Discovery, 2021

Immunogenicity of CAR T cells in cancer therapy
Wagner et al, Nature Review Clinical Oncology, 2021

Regulatory T cells for minimizing immune suppression in kidney transplantation: phase I/IIaclinical trial
Roemhild et al, BMJ, 2020

CAR T-cell product performance in haematological malignancies before and after marketing authorization
Elsallab et al, Lancet Oncology, 2020

Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy
Fritsche et al, Trends in Biotechnology, 2020

Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals
Elsallab et al, Molecular Therapy – Methods & Clinical Development 2020

Cell and Gene Therapy Trials: Are We Facing an ‘Evidence Crisis’?
Abou-el-Enein and Hey, Lancet eClinicalMedicine, 2019

A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions
Bauer et al, Stem Cells Translational Medicine, 2018

Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment
Abou-el-Enein et al, Cell Stem Cell, 2017

The business case for cell and gene therapies
Abou-el-Enein et al, Nature Biotechnology, 2014